GlycoMimetics Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (23)

Latest Posts

About This Stock More About This Stock
Late Slide In Tech Mega-Caps Leaves Averages Mixed For Week
Article By: The Fly
Saturday, June 10, 2017 10:38 AM EDT
Stocks appeared in line for a slight weekly advance until Friday afternoon, when a sharp decline in a number of mega-cap tech stock pushed the Nasdaq down nearly 2.5% at its low point.
In this article: DFT, DHI, DLR, FOR, JWN, M, THO, VZ, CLDR, AMRI, GIII, NLNK, AAPL, AMZN, FRAN, GOOG, MSFT, YHOO, DVAX, JUNO, BABA, FB, AMBA, GLYC, KITE, BLUE, MIK, ANTM, PLAY, RDUS, LOXO, DLTH, HDS
Read
Biotech Fades After ASCO Abstract Rally
Article By: Rod Raynovich
Friday, May 26, 2017 6:29 PM EDT
Biotechs faded today now that the rush of oncology drug news cooled down. Today was dominated by the “red screen” with profit taking mainly in smaller caps and momentum driven oncology stocks.
In this article: MRK, ALNY, ALXN, BMRN, INCY, CELG, CLVS, VRTX, ZIOP, JUNO, PBYI, EPZM, GLYC, KITE, TSRO
Read
ASCO Abstracts Week: Biotech Trends And Hot Stocks
Article By: Rod Raynovich
Monday, May 22, 2017 10:58 PM EDT
Today Amgen was down over 2 % on news that its osteoporosis treatment Evenity is unlikely to win FDA approval this year because of a safety risk. Radius Health was up over 6% to $37.30 as their rival drug Tymlos was approved in April.
In this article: MRK, ALNY, IBB, INCY, REGN, AMGN, CLVS, VRTX, FBT, XBI, PUMA, JUNO, EPZM, GLYC, KITE, BLUE, RDUS
Read
GlycoMimetics Surges 100% On Breakthrough Therapy Designation
Article By: Terry Chrisomalis
Sunday, May 21, 2017 11:52 PM EDT
On Thursday, GlycoMimetics surged as high 100% after the company announced that it had received FDA breakthrough therapy designation.
In this article: GLYC
Read
GlycoMimetics - High Potential Clinical-Stage Biotech
Article By: Scott Matusow
Tuesday, May 16, 2017 9:01 AM EDT
GlycoMimetics is a clinical-stage biotech that we feel has significant potential to be a short, mid, and long term winner. The company has a unique and novel platform in which early data looks very promising.
In this article: GLYC Also: BMY, PFE, JAZZ, CALA
Read

PARTNER HEADLINES

Latest Tweets for $GLYC

No tweets yet!